Millioni Chhabra
HIV Scientist
North Carolina, USA
Investors Our investor proposition
GSK is a science-led global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical, vaccine and consumer healthcare products.
Key information
2017 first quarter results - released on 26 April 2017
We released our Q1 2017 results on 26 April 2017.
View our first quarter results in full
Latest information
Latest press releases
- GSK starts phase III study with mepolizumab in patients with nasal polyps
- GSK receives CHMP positive opinion for Synflorix pneumococcal vaccine four-dose vial
- GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC’s Advisory Meeting
Annual Report and Responsible Business Supplement 2016
View our Annual Report 2016 summary and download the full Annual Report and Responsible Business Supplement.